ClinicalTrials.gg
RecruitingNCT06451757KH176-301Updated Oct 14, 2026

KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases

A Phase 3 interventional study of Sonlicromanol and Placebo in Mitochondrial Diseases, Maternally Inherited Diabetes and Deafness (MIDD) and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS), sponsored by Khondrion BV. Recruiting at 10 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Primary conditionMELAS SyndromeRegistry: Mitochondrial DiseasesReclassifiedWhy we changed it
Registry
Mitochondrial Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
MELAS Syndrome
Why
  1. The study's listed conditions name MELAS Syndrome, a narrower term within Mitochondrial Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Khondrion BV · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 14, 2026Site recruiting status changedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in MELAS Syndrome with a site in United States — 6 open to participants now, 6 under way, 1 of them phase 3. MELAS Syndrome · United States.

Planned enrollment
Largest of 15
220 · median 27
Started
2026
the only one that year
Phase 3
2 of 21
1 open now
Registered
19th of 21
by date
Lead sponsor
1 of 21
Khondrion BV

Among the 21 studies in MELAS Syndrome with a site in United States, this one has the largest planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2026, is one of 2 in phase 3, and was the 19th registered.

MELAS Syndrome

37 studies on the registry are indexed under MELAS Syndrome; 8 are open to participants now.

Browse MELAS Syndrome studies →

Open to participants now

6 of the 21 studies in MELAS Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 MELAS Syndrome studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in MELAS Syndrome with a site in United States, or all of them as a file.
02

Study summary

The KHENERFIN study aims to determine whether the study medicine, sonlicromanol, is able to reduce symptoms of fatigue and the impact of fatigue on daily life, and whether sonlicromanol is able to improve physical abilities of people like balance control and lower limb skeletal muscle strength in people with mitochondrial disease.

In this study, the effects of sonlicromanol are compared against a placebo, a tablet identical in appearance and taste but without the active drug. Participants take either sonlicromanol or placebo twice daily for a treatment duration of 52 weeks.

In addition to these primary objectives, the study evaluates the efficacy of sonlicromanol on secondary and exploratory outcomes, as well as its safety and tolerability after one year of treatment.

Read the detailed description

The KHENERFIN study is investigating the medicine sonlicromanol. The study aims to see if sonlicromanol can reduce symptoms of fatigue and reduce the impact of fatigue on daily life. The study also investigates if sonlicromanol improves physical abilities like balance control and lower limb skeletal muscle strength in people with mitochondrial disease. In addition to these primary objectives, the study evaluates the efficacy of sonlicromanol on selected secondary and exploratory outcomes. It also assesses the safety and tolerability of sonlicromanol.

This study is a placebo controlled, double blind study; the effects of sonlicromanol will be compared with a placebo (study medication that looks like the actual study medicine but contains no active medicine). Neither the participants nor the study team know who is receiving the study medicine or placebo. Participants cannot change their assigned rreatment.

During the screening period, which lasts a maximum of 4 weeks, it is assessed whether the potential participant meets all requirements to participate in the study. Patients who complete the screening phase and are enrolled in the study are randomly (by chance) assigned to receive either the study medicine sonlicromanol or placebo (no active medication). Participants have an equal chance of receiving either sonlicromanol or a placebo. A final follow-up visit is scheduled 2 weeks after taking the last dose of study medication. Total study duration is approximately 60 weeks.

Sonlicromanol will be supplied in tablet form, containing 90 mg of sonlicromanol (equivalent to 100 mg of sonlicromanol.HCl), with the tablets embossed accordingly or provided as a placebo. The study medication must be taken twice daily during the treatment period of 52 weeks. Up to 220 subjects with a confirmed mitochondrial DNA tRNALeu(UUR) 3243A>G mutation will be randomly assigned in a 1:1 ratio to receive either sonlicromanol or placebo.

03

Conditions studied

  • Mitochondrial Diseases
  • Maternally Inherited Diabetes and Deafness (MIDD)
  • Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)
  • Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation

Browse trials for

Keywords

  • Mitochondrial Diseases
  • Oxidative Phosphorylation (OXPHOS)
  • Maternally Inherited Diabetes and Deafness (MIDD)
  • Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
  • Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS)
  • Sonlicromanol
04

In context

MELAS Syndrome Reclassified

37 studies on the registry are indexed under MELAS Syndrome; 8 are open to participants now.

This study's planned enrollment of 220 is above the median of 24 across 29 interventional studies indexed under MELAS Syndrome.

Browse MELAS Syndrome studies →

Lead sponsor

Khondrion BV is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Compared within MELAS Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Mitochondrial Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

The criteria were revised on the registry on Oct 14, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed
  2. Males and females aged ≥18 years with a multi-system primary mitochondrial disease.
  3. A confirmed mitochondrial DNA tRNALeu(UUR) m.3243A>G mutation (m.3243A>G PMD) plus an age adjusted heteroplasmy percentage ≥ 20% in white blood cells [=blood heteroplasmy/0.977(age+12)]. Or in urine (urinary epithelial cells), or buccal smear or skeletal muscle (results (obtained per local guidance) ≥ 20% must be available prior to the subject being randomized).
  4. Presence of chronic fatigue (not attributable to other etiologies than PMD):

    1. Patient self-reported chronic fatigue for at least 3 months prior to the Screening Visit and recorded in the clinical patient files; AND
    2. Presence of fatigue (raw total score >22), assessed by Neuro-QoL SFv1-F at Screening.
  5. Presence of mitochondrial myopathy defined as:

5xSST at Screening and Baseline should be ≥ 11 seconds and participant must demonstrate the ability to complete the test at baseline (i.e., complete the test within 30 seconds).

6. Other Inclusion criteria per protocol.

Exclusion criteria

Exclusion criteria

  1. Treatment with any IMP within 3 months (or 5 times the half-life of the IMP, whichever is longer) prior to screening or plans to use an IMP (other than the study intervention) during the study.
  2. Bone deformities, motor abnormalities or chronic ulcers that in the opinion of the PI may interfere with and/or confound the interpretation of the subject's performance during the 5 times sit to stand test (5XSST).
  3. Surgery of gastrointestinal tract that might interfere with drug absorption. Or severe GI dysmotility, chronic vomiting, diarrhea, bouts of pseudo-obstruction which will impair appropriate IMP absorption in the opinion of the investigator.
  4. respiratory disease and/or cardiac disease (medical history or current clinical findings) in the opinion of the investigator.
  5. Prior interventional cardiac procedure (e.g., cardiac catheterization, angioplasty/percutaneous coronary intervention, balloon valvuloplasty, etc.) within 3 months prior to screening.
  6. Structural heart disease based on cardiac MRI or Echocardiography (e.g., clinically significant valve disease; i.e., aortic or mitral valve stenosis or regurgitation) and / or Left ventricular dysfunction ( \<52% in men and \< 54% in women) and / or congestive cardiac failure (more severe than grade II) and / or Maximum left-ventricular septal or posterior wall thickness > 15 mm and / or Evidence of active myocardial ischaemia, evidence and / or recent history of myocardial infarction (\< 6-months) and / or coronary angioplasty / coronary bypass surgery (\< 12 months).
  7. Family history of unexplained/uninvestigated syncope or congenital long and short syndrome or sudden death (under the age of 60) and / or Abnormal QTcF interval [QTcF > 450 msec (men) or QTcF > 470 msec (women) = abnormally long QTcF or QTcF \< QT \< 320ms = abnormally short QtcF] and / or Intermittent or persistent WPW (pre-excitation) syndrome on ECG [ie: abnormally wide QRS > 120ms with slurred up-stroke ('delta' wave) and PR-interval \< 120ms] and / or ECG evidence of atrial fibrillation (permanent, persistent or paroxysmal) and / or

    High grade AV Block [2nd-degree AV block Type II (ie: 2:1) or complete AV block (3rd degree) or intermittent conduction system abnormalities with the exception of any of the following:

    • 1st degree atrioventricular (AV)-block
    • 2nd degree AV-block Type 1 (Mobitz Type 1 / Wenckebach type)
    • Right bundle branch block.
  8. History of acute heart failure (within the last 3 months).
  9. Higher degree of AV-blocks (AVB II° or III°).
  10. Other exclusion criteria per protocol
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Sonlicromanol (KH176)

    Administration of 90 mg sonlicromanol (equivalent to 100 mg sonlicromanol.HCl) twice daily

    Drug: Sonlicromanol

  • Placebo comparator
    Matching Placebo

    Administration of 100 mg matching placebo twice daily

    Drug: Placebo

Interventions

  • DrugTroloxStudies of TroloxTrolox pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administration of 90 mg sonlicromanol (100 mg sonlicromanol.HCl) twice daily during 52 weeks

  • DrugPlacebo

    Administration of 100 mg placebo twice daily during 52 weeks

07

What researchers measure

Primary outcomes

  1. Neuro-QoL Fatigue Short Form v1

    Change from baseline compared to placebo at week 52 and at other relevant study visits of the Quality of Life in Neurological Disorders Fatigue Short Form version 1 (Neuro-QoL Fatigue - SF v1): The Neuro-QoL Fatigue SF v1 is an 8-item self-assessment questionnaire evaluating the perception of fatigue and its impact in daily life activities. Each question is scored as following: 1=Never, 2=Rarely, 3=Sometimes, 4=Often, and 5=Always. Total raw scores range from 8-40. T-scores are calculated from the short form scoring table provided in the instruments´ manual. T-score distributions rescale raw scores into standardized scores with a mean of 50 and a standard deviation (SD) of 10. Change from baseline: Negative numbers mean less fatigue, better outcome, positive score means more fatigue, worse outcome.

    Time frame: Screening, Baseline (Day 1), Weeks 13, 26, 39, 52 (End of Trial Visit)

  2. Five Times Sit-To-Stand Test (5XSST)

    Change from Baseline compared to placebo at week 52 and at other relevant study visits of the 5xSST in total time (in seconds) to complete the 5xSTS. The 5xSST scoring is based on the amount of time (to the nearest decimal in seconds a subject is able to transfer from a seated to a standing position and back to sitting five times. Inability to complete five repetitions without assistance or use of upper extremity support indicates 'failure to perform of test, any modifications should be documented. Participant is directed to stand up straight as quickly as possible 5 times, without stopping in between, keeping arms folded across the chest. When 5xSST is not reached within 30.0 seconds the test is stopped and the actual number of sit to stands reached within those 30 seconds is recorded. Faster times (in sec) denotes better performance.

    Time frame: Screening, Baseline (Day 1), Weeks 13, 26, 39, 52 (End of Trial Visit)

Secondary outcomes

  1. 36-Item Short Form Survey (SF-36)

    Change from Baseline at week 52 and at other relevant study visits of the 36-item Short Form Survey Instrument (SF-36). SF36 is a 36-item multidimensional self-report health related quality of life (HRQoL) questionnaire, containing 36 items measuring eight dimensions of HRQoL: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100. Standard scoring algorithms yield two distinct, higher-order summary scores: Physical Component Summary (PCS) and Mental Component Summary (MCS). Higher scores on all subscales represent better health and functioning.

    Time frame: Baseline (Day 1), Weeks 13, 26, 39, 52 (End of Trial Visit)

  2. The PROMIS Fatigue Primary Mitochondrial Disease Short Form (PROMIS) Fatigue PMD SF)

    Change from baseline at week 52 and at other relevant study visits of the Patient-Reported Outcomes Measurement Information System (PROMIS®) Fatigue Primary Mitochondrial Disease Short Form (PROMIS Fatigue PMD SF). The PROMIS Fatigue Primary Mitochondrial Disease Short Form is a nine-item self-report inventory to assess fatigue symptoms and impacts on daily living measured in PMD. The PROMIS Fatigue PMD SF asks the respondent to rate the experience and impact of fatigue symptoms by asking how often they feel or experienced specific fatigue symptoms in the past seven days on a 5-point rating scale scored as: "never" (1), "rarely" (2), "sometimes" (3), "often" (4), "always" (5). Higher scores indicate greater fatigue severity.

    Time frame: Screening, Baseline (Day 1), Weeks 13, 26, 39, 52 (End of Trial Visit)

  3. Beck Depression Inventory-2 (BDI-2)

    Change from Baseline compared to placebo at week 52 and at other relevant study visits of the Beck Depression Inventory (BDI). The Beck Depression Inventory (BDI) is a 21-question multiple-choice self-report inventory, for measuring the severity of depression. It is composed of items relating to symptoms of depression such as hopelessness and irritability, cognitions such as guilt or feelings of being punished, as well as physical symptoms such as fatigue, weight loss, and lack of interest in sex. Each answer is scored on a scale value of 0 to 3; higher scores indicate more severe depressive symptoms.

    Time frame: Screening, Baseline (Day 1), Weeks 13, 26, 39, 52 (End of Trial Visit)

  4. Patient-scored Global Impression of Severity scale (PGI-S)

    Change from Baseline compared to placebo at week 52 and at other relevant study visits of the Patient Global Impression of Severity (PGI-S).The Patient scored Global Impression - Severity questionnaire assesses patient's impression of disease severity. The PGI-S item asks the respondent to rate the severity of their PMD symptoms at the time of assessment ("Please choose the response that best describes the severity of your Primary Mitochondrial Disease (PMD) symptoms today") on a 7-point scale scored as: "none" (1), "very mild" (2), "mild" (3), "moderate" (4), "moderately severe" (5), "severe", (6), or "extremely severe" (7). Higher scores indicate a higher level of severity.

    Time frame: Baseline (Day 1), Weeks 13, 26, 39, 52 (End of Trial Visit)

  5. Clinician-scored Global Impression of Severity (CGI-S)

    Change from Baseline compared to placebo at week 52 and at other relevant study visits of the Clinician Global Impression of Severity (CGI-S). The Clinician scored Global Impression - Severity (CGI-S) scale is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. The CGI-S asks the clinician one question: "Considering your total clinical experience with this particular population, how ill is the patient at this time?" which is rated on the following seven-point scale: "normal, not at all ill" (1), "borderline" (2), "mild" (3), "moderate" (4), or "marked" (5), "severe" (6), and "among the most extremely affected patients" (7). This rating is based upon observed and reported symptoms, behaviour, and function at the time of the assessment.Higher scores indicate a higher level of severity.

    Time frame: Baseline (Day 1), Weeks 13, 26, 39, 52 (End of Trial Visit)

Other outcomes

  1. Newcastle Mitochondrial Disease Adult Scale (NMDAS)

    Change from Baseline compared to placebo at week 52 and at other relevant study visits of the Newcastle Mitochondrial Disease Scale for Adults (NMDAS). The NMDAS is a semi-quantitative clinical rating scale designed specifically for all forms of mitochondrial disease. The rating scale encompasses all aspects of mitochondrial disease by exploring several domains: current function, system specific involvement, and current clinical assessment. Each question/item in the NMDAS has a possible score from 0-5. Each of the three section scores are calculated by simply summing the scores obtained for each question in that section, with the higher the score the more severe the disease. Thus, scores can range from 0 to 50 for Sections I and III, and from 0 to 45 for Section II, and from 0 to 145 for Sections I through III. Higher scores indicate a higher level of disease severity.

    Time frame: Baseline (Day 1), Weeks 26, 52 (End of Trial Visit)

  2. Brief Pain Inventory Short Form (BPI-SF)

    Change from Baseline compared to placebo at week 52 and at other relevant study visits of the Brief Pain Inventory-Short Form (BPI-SF). The BPI-SF is a validated (33) self-administered questionnaire to assess the severity of pain and the impact of pain on the patient's daily functions. BPI-SF evaluates pain severity at its worst, least, and average during the last 24 hours, as well as current pain level, with 0 representing no pain and 10 the worst pain imaginable. Seven items measuring interference with daily functioning (general activity, walking, work, mood, relations with others, sleep, and enjoyment of life) are also assessed on an 11-point scale, where 0 represents no interference and 10 complete interferences. The scores can be averaged to the two components of the BPI SF score, the Pain Severity Index and the Pain Interference Index. Higher scores indicate a higher level of severity and impact of pain.

    Time frame: Baseline (Day 1), Weeks 13, 26, 39, 52 (End of Trial Visit)

  3. Health Economics and Outcomes Research (HEOR) Assessments: EQ-5D-5L

    Change from Baseline compared to placebo at week 52 and at other relevant study visits of the EQ-5Dimension-5 Level (EQ-5D-5L). The EQ-5D-5L is a self-report health-related quality of life (HRQoL) instrument consisting a descriptive system and a visual analogue scale (EQ-VAS). The descriptive system that defines health in five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response categories (levels): no problems, slight problems, moderate problems, severe problems and extreme problems. The EQ-VAS records the respondent's self-rated health on a vertical VAS. The respondents can report their perceived health status with a grade ranging from 0 ('the worst health you can imagine') to 100 ('the best health you can imagine'). A higher score denotes a worse health state.

    Time frame: Screening, Baseline (Day 1), Weeks 13, 26, 39, 52 (End of Trial Visit) and at week 54 (Follow-up)

  4. Columbia-Suicide Severity Rating Scale (C-SSRS)

    Change from Baseline compared to placebo at week 52 and at other relevant study visits of the Columbia-Suicide Severity Rating Scale (C-SSRS). The instrument assesses severity of suicidal ideation ("severity subscale"), rated on a 5-point ordinal scale, the intensity of ideation subscale ("intensity subscale"), comprising 5 items, rated on a 5-point ordinal scale: frequency, duration, controllability, deterrents, and reason for ideation, resulting in 0-25 score range summed from five items, with higher scores indicating more severe suicidal ideation. A score of 0 indicates that no suicide ideation is present. The behaviour subscale is a nominal scale including actual, aborted, and interrupted attempts; preparatory behaviour; and self-injurious behaviour. The lethality subscale assesses actual attempts; actual lethality rated on a 6-point ordinal scale. Higher scores indicate a higher level of severity.

    Time frame: Screening, Baseline (Day 1), Weeks 13, 26, 39, 52 (End of Trial Visit)

  5. Gastro-Intestinal symptoms.

    Change from Baseline compared to placebo on the number of gastro-intestinal complaints, intensity and duration. The number of gastro-intestinal complaints/month will be captured, starting at screening until (and including) the week 52 visit. For this purpose the Gastro-Intestinal symptoms questionnaire will be used.

    Time frame: Through week 52

  6. Seizure episodes

    Change from Baseline compared to placebo on the number of seizures, intensity and duration and on the use of medication. Seizure data (e.g., occurrence, duration, intensity severity; and any use of migraine medication) are captured daily through a daily headache-diary.

    Time frame: Through week 52

  7. Safety and tolerability assessed by nature, frequency and severity of treatment emergent adverse events (TEAEs)

    Safety and tolerability assessed by nature, frequency and severity of treatment emergent adverse events (TEAEs) Treatment emergent adverse events will be coded using medical dictionary for regulatory activities (MedDRA). A TEAE is defined as an adverse event (AE) observed after starting administration of the investigational product (IP) to 14 days after last dose of IP. An AE is any untoward medical occurrence in a participant, temporally associated with the use of IP, whether or not considered related to the IP. An AE can therefore be any unfavourable and unintended, symptom, or disease (new or exacerbated) temporally associated with the use of IP.

    Time frame: Through Week 52

  8. Safety: 12 lead ECG parameters: QRS duration (milliseconds)

    12 lead ECG parameter data QRS duration (milliseconds) will be summarised.

    Time frame: Baseline (Day 1), Weeks 13, 26, 39, 52 (End of Trial Visit)

  9. Safety: 12 lead ECG parameters: QRS morphology (peak, axis)

    12 lead ECG parameter data QRS morphology (peak, axis) will be summarised.

    Time frame: Baseline (Day 1), Weeks 13, 26, 39, 52 (End of Trial Visit)

  10. Safety: 12 lead ECG parameters: QTcF (Fridericia)

    12 lead ECG parameter data QTcF (Fridericia) will be summarised.

    Time frame: Screening, Baseline (Day 1), Day 6, Weeks 4, 8, 13, 26, 39, 52 (End of Trial Visit), 54 (Safety FU)

  11. Safety: 12 lead ECG parameters: PQ interval: milliseconds (ms))

    12 lead ECG parameter data PQ intervals (milliseconds) will be summarised.

    Time frame: Screening, Baseline (Day 1), Day 6, Weeks 4, 8, 13, 26, 39, 52 (End of Trial Visit), 54 (Safety FU)

  12. Safety: 12 lead ECG parameters: Heart rate: beats per minute (bpm)

    12 lead ECG parameter data Heart rate (beats per minute (bpm) be summarised.

    Time frame: Screening, Baseline (Day 1), Day 6, Weeks 4, 8, 13, 26, 39, 52 (End of Trial Visit), 54 (Safety FU)

  13. Safety: 12 lead ECG parameters: Tpeak-Tend interval

    12 lead ECG parameter data (Tpeak-Tend interval) will be summarised.

    Time frame: Screening, Baseline (Day 1), Day 6, Weeks 4, 8, 13, 26, 39, 52 (End of Trial Visit), 54 (Safety FU)

  14. Safety: 12 lead ECG parameters: T wave morphology (peak, symmetry)

    12 lead ECG parameter data T-wave morphology (symmetry) will be summarised.

    Time frame: Screening, Baseline (Day 1), Day 6, Weeks 4, 8, 13, 26, 39, 52 (End of Trial Visit), 54 (Safety FU)

  15. Safety: Incidence of laboratory abnormalities, based on haematology, clinical chemistry, and urinalysis test results

    Incidence of laboratory abnormalities outside the clinical reference ranges based on haematology, serum biochemistry, and urinalysis test

    Time frame: Screening, Baseline (Day 1), Weeks 4, 8, 13, 26, 39, 52 (End of Trial Visit)

  16. Safety: Vital signs abnormalities and/or AEs

    Incidence of clinically significant vital sign values.

    Time frame: Screening, Baseline (Day 1), Weeks 26, 52 (End of Trial Visit),54 (Safety FU)

  17. Pharmacokinetics: Tmax (hours)

    Tmax: Time to reach maximum (peak) plasma concentration following drug administration (hours)

    Time frame: Week 39: pre-dose, and at 1, 2, 4, 6, 8 hours post dosing.

  18. Pharmacokinetics: Cmax (ng/mL)

    Maximum (peak) plasma drug concentration in ng/mL

    Time frame: Week 39: pre-dose, and at 1, 2, 4, 6, 8 hours post dosing.

  19. Pharmacokinetics: Ctrough (ng/mL)

    Plasma concentration (measured concentration at the end of a dosing interval at steady state in ng/mL

    Time frame: Week 39: pre-dose, and at 1, 2, 4, 6, 8 hours post dosing.

  20. Pharmacokinetics: AUCinf (h*ng/mL)

    Area under the plasma concentration time curve from time zero to infinity in h\*ng/mL

    Time frame: Week 39: pre-dose, and at 1, 2, 4, 6, 8 hours post dosing.

  21. Pharmacokinetics: AUCtau (h*ng/mL)

    Area under the plasma concentration time curve in h\*ng/mL

    Time frame: Week 39: pre-dose, and at 1, 2, 4, 6, 8 hours post dosing.

  22. Pharmacokinetics: T1/2 (hours)

    Terminal Elimination Half-life

    Time frame: Week 39: pre-dose, and at 1, 2, 4, 6, 8 hours post dosing.

08

Study locations

7 of 10 sites recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Not yet recruiting
  • Cleveland Clinic Neurological Institute Mellen Center
    Cleveland, Ohio 44195, United States
    Not yet recruiting
    • Jamie Jobson · Contactjobsonj@ccf.org
    • Sumit Parikh, Dr. · Principal investigator
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
    Recruiting
  • Rigshospitalet, University of Copenhagen
    Kopenhagen, Region Sjælland DK2100, Denmark
    Recruiting
  • CHU de Bordeaux - Hôpital Pellegrin Service Gynecologie Obstetrique
    Bordeaux, Gironde 33000, France
    Not yet recruiting
  • Groupe Hospitalier Pitie-Salpetriere - Charles-Foix Clinical Investigation Center Paris-Est
    Paris, Paris 75013, France
    Recruiting
  • Klinikum der Universität München Friedrich-Baur-Institut
    München, 80336, Germany
    Recruiting
    • Natalie Adriana Villalobos Trigueros · Contactnatalie.villalobos@med.uni-muenchen.de · +49 89/4400-57402
    • Thomas Klopstock, Prof. Dr. · Principal investigator
    • Boriana Buechner, Dr. · Sub investigator
  • Fondazione IRCCS Istituto Neurologico Carlo Besta
    Milan, 20133, Italy
    Recruiting
  • Radboud University Medical Center
    Nijmegen, Gelderland 6525, Netherlands
    Recruiting
  • University College London Hospitals NHS Foundation Trust National Hospital for Neurology and Neurosurgery
    London, Greater London WC1N 3BG, United Kingdom
    Recruiting
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2026 (actual). Primary completion is estimated for Sep 2029, 41 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Sep 2028 → Sep 2029 and completion Sep 2028 → Sep 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2024
First posted
Jun 11, 2024
StartActual
Apr 14, 2026
Primary completionEst.
Sep 2029was Sep 2028
CompletionEst.
Sep 2029was Sep 2028
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Rigshospitalet, University of Copenhagen · Kopenhagen, DenmarkNot yet recruiting→Recruiting
  • Groupe Hospitalier Pitie-Salpetriere - Charles-Foix Clinical Investigation Center Paris-Est · Paris, FranceNot yet recruiting→Recruiting
Oct 14, 2026
Primary completion
Sep 2028→Sep 2029
Oct 14, 2026
Study completion
Sep 2028→Sep 2029
Oct 14, 2026
Eligibility
2 exclusion criteria edited, 3 added, 3 removed
What changed in the criteria
Exclusion criteria
  • RemovedQTcF > 450 msec (men) or QTcF > 470 msec (women).
  • RemovedStructural heart disease based on cardiac MRI or Echocardiography (e.g., clinically significant valve disease; i.e., aortic or mitral valve stenosis or regurgitation) and/or abnormal conduction (QRS >120 msec, PR < 120 msec), and/or repolarization (QTcF > 450 msec (men) or QTcF > 470 msec (women)). Myocardial function (LVEF <52% in men and < 54% in women), symptomatic ischemic heart disease (inducible ischemia or coronary obstruction), and/or pathologic hypertrophy (e.g. > 15mm septal or posterior wall thickness), that is not well controlled under current specialized care. Subjects with congestive heart failure class II and above should also be excluded.
  • RemovedFamily history of unexplained/uninvestigated syncope or congenital long and short QT syndrome or sudden death (under the age of 60). ECG evidence of acute or recent ischemia, acute or Recent Myocardial Infraction, atrial fibrillation, high grade AV Blocks (Second Degree AV Block Type II or Third-degree AV Block), complete Heart Block or active conduction system abnormalities with the exception of any of the following:
  • AddedStructural heart disease based on cardiac MRI or Echocardiography (e.g., clinically significant valve disease; i.e., aortic or mitral valve stenosis or regurgitation) and / or Left ventricular dysfunction (LVEF <52% in men and < 54% in women) and / or congestive cardiac failure (more severe than grade II) and / or Maximum left-ventricular septal or posterior wall thickness > 15 mm and / or Evidence of active myocardial ischaemia, ECG evidence and / or recent history of myocardial infarction (< 6-months) and / or coronary angioplasty / coronary bypass surgery (< 12 months).
  • AddedFamily history of unexplained/uninvestigated syncope or congenital long and short QT syndrome or sudden death (under the age of 60) and / or Abnormal QTcF interval [QTcF > 450 msec (men) or QTcF > 470 msec (women) = abnormally long QTcF or QTcF < QT < 320ms = abnormally short QtcF] and / or Intermittent or persistent WPW (pre-excitation) syndrome on ECG [ie: abnormally wide QRS > 120ms with slurred up-stroke ('delta' wave) and PR-interval < 120ms] and / or ECG evidence of atrial fibrillation (permanent, persistent or paroxysmal) and / or
  • AddedHigh grade AV Block [2nd-degree AV block Type II (ie: 2:1) or complete AV block (3rd degree) or intermittent conduction system abnormalities with the exception of any of the following:
  • EditedFirst1st degree atrioventricular (AV)-block
  • EditedSecond2nd degree AV-block Type 1 (Mobitz Type 1 / Wenckebach type)
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Rigshospitalet, University of Copenhagen · Kopenhagen, DenmarkNot yet recruiting→Recruiting
    • Groupe Hospitalier Pitie-Salpetriere - Charles-Foix Clinical Investigation Center Paris-Est · Paris, FranceNot yet recruiting→Recruiting
    Primary completion Sep 2028→Sep 2029
    Study completion Sep 2028→Sep 2029
    Eligibility 2 exclusion criteria edited, 3 added, 3 removed
    What changed in the criteria
    Exclusion criteria
    • RemovedQTcF > 450 msec (men) or QTcF > 470 msec (women).
    • RemovedStructural heart disease based on cardiac MRI or Echocardiography (e.g., clinically significant valve disease; i.e., aortic or mitral valve stenosis or regurgitation) and/or abnormal conduction (QRS >120 msec, PR < 120 msec), and/or repolarization (QTcF > 450 msec (men) or QTcF > 470 msec (women)). Myocardial function (LVEF <52% in men and < 54% in women), symptomatic ischemic heart disease (inducible ischemia or coronary obstruction), and/or pathologic hypertrophy (e.g. > 15mm septal or posterior wall thickness), that is not well controlled under current specialized care. Subjects with congestive heart failure class II and above should also be excluded.
    • RemovedFamily history of unexplained/uninvestigated syncope or congenital long and short QT syndrome or sudden death (under the age of 60). ECG evidence of acute or recent ischemia, acute or Recent Myocardial Infraction, atrial fibrillation, high grade AV Blocks (Second Degree AV Block Type II or Third-degree AV Block), complete Heart Block or active conduction system abnormalities with the exception of any of the following:
    • AddedStructural heart disease based on cardiac MRI or Echocardiography (e.g., clinically significant valve disease; i.e., aortic or mitral valve stenosis or regurgitation) and / or Left ventricular dysfunction (LVEF <52% in men and < 54% in women) and / or congestive cardiac failure (more severe than grade II) and / or Maximum left-ventricular septal or posterior wall thickness > 15 mm and / or Evidence of active myocardial ischaemia, ECG evidence and / or recent history of myocardial infarction (< 6-months) and / or coronary angioplasty / coronary bypass surgery (< 12 months).
    • AddedFamily history of unexplained/uninvestigated syncope or congenital long and short QT syndrome or sudden death (under the age of 60) and / or Abnormal QTcF interval [QTcF > 450 msec (men) or QTcF > 470 msec (women) = abnormally long QTcF or QTcF < QT < 320ms = abnormally short QtcF] and / or Intermittent or persistent WPW (pre-excitation) syndrome on ECG [ie: abnormally wide QRS > 120ms with slurred up-stroke ('delta' wave) and PR-interval < 120ms] and / or ECG evidence of atrial fibrillation (permanent, persistent or paroxysmal) and / or
    • AddedHigh grade AV Block [2nd-degree AV block Type II (ie: 2:1) or complete AV block (3rd degree) or intermittent conduction system abnormalities with the exception of any of the following:
    • EditedFirst1st degree atrioventricular (AV)-block
    • EditedSecond2nd degree AV-block Type 1 (Mobitz Type 1 / Wenckebach type)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06451757
Lead sponsor
Khondrion BV
Responsible party
Sponsor
First posted
Jun 11, 2024
Start date
Apr 14, 2026
Primary completion
Sep 2029 (estimated)
Completion
Sep 2029 (estimated)
Last update
Oct 14, 2026

Study contacts

Jasper Levink, MSc.
Contact
Khenerfin@khondrion.com
+31 24 7635000
G. Ruiterkamp, MSc.
Contact
Khenerfin@khondrion.com
+31 24 7635000

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trolox

Start the discussion